Moxetumomab pasudotox as monotherapy is indicated for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (PNA).<\/p>\n
Moxetumomab pasudotox, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL. The drug consists of the binding fragment (Fv) of an anti-CD22 antibody fused to a toxin called PE38.[5] This toxin is a 38 kDa fragment of Pseudomonas exotoxin A.<\/p>\n
Hairy cell leukemia (HCL) is a rare, slow-growing cancer of the blood in which the bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. HCL is named after these extra B cells which look \u201chairy\u201d when viewed under a microscope.[4] As the number of leukemia cells increases, fewer healthy white blood cells, red blood cells and platelets are produced.<\/p>\n
If moxetumomab pasudotox-tdfk for injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
LUMOXITI (moxetumomab pasudotox-tdfk) for injection, for intravenous use Initial U.S. Approval: 2018<\/p>\n","protected":false},"excerpt":{"rendered":"
Lumoxiti (moxetumomab pasudotox) is a CD22-directed cytotoxin indicated for adult patients with advanced hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).<\/p>\n
DISEASE INDICATIONS-Leukemia
\nMANUFACTURER-AstraZeneca Pharmaceuticals LP
\nUSAGE-Intravenous
\nMEDICINE APPROVED BY-European Medical Agency (EMA), Food and Drug Administration (FDA)<\/p>\n
Summary of FDA-approved use on approval date: Click Here<\/a> If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a>\u00a0in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201csotorasib tablets\u201d based on the information you provide.<\/p>\n
\n(see Drugs@FDA for complete indication)<\/p>\nFull Support:<\/h4>\n